US4699877A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for detecting human tumors
Assignee: University of California
•
Filing: 1984-11-20
•
Granted: 1987-10-13
•
Expires: 2004-11-20
Abstract
Abstract Methods and compositions for detecting the presence of tumors are provided, where a physiological sample is assayed for the expression product of a c-onc gene as diagnostic for the presence of the tumor. The method finds use in both pre- and postoperative situations with a host suspected of having transformed malignant cells.
Inventors
- 👤 Martin J. Cline
- 👤 Dennis J. Slamon
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:22
CPC Classifications
C; C12; C12N; C12N15/00; C07; C07K; C07K14/00; C07K14/82; C07K16/00; C07K16/18; C07K16/32; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883; C12Q1/6886; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/575; G01N33/57505; G01N33/57575; G01N33/5758; A; A61; A61K; A61K39/00; C12Q2600/00; C12Q2600/158; G01N2333/00; G01N2333/82; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/813; Y10S530/00; Y10S530/82; Y10S530/826; Y10S530/827; Y10S530/828; Y10S930/00; Y10S930/01; Y10S930/22; Y10S930/221
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
118 words
A method for evaluating the probability of cellular malignancy in a human host, said method comprising: bringing into close association (1) a probe specific for a cellular product, said cellular product being mRNA or its expression product, where said mRNA is complementary to a DNA sequence of a retrovirus capable of transforming a normal cell to malignancy and said probe is a nucleic acid sequence capable of duplexing with said mRNA or antibody capable of binding to said expression product, and (2) a source from said human host suspected of containing cellular product; and determining the level of binding of said probe to said cellular product, wherein an elevated level is indicative of the presence of cellular malignancy.
Claim 2
Independent Claim
118 words
A method for evaluating the probability of cellular malignancy in a human host, said method comprising: bringing into close association (1) a probe specific for a cellular product, said cellular product being mRNA or its expression product, where said mRNA is complementary to a DNA sequence of a retrovirus capable of transforming a normal cell to malignancy and said probe is a nucleic acid sequence capable of duplexing with said mRNA or antibody capable of binding to said expression product, and (2) a source from said human host suspected of containing cellular product; and determining the level of binding of said probe to said cellular product, wherein an elevated level is indicative of the presence of cellular malignancy.
Claim 3
Dependent Claim
15 words
A method according to claim 1, wherein said source is cells from said human host.
Claim 4
Dependent Claim
17 words
A method according to claim 1, wherein said source is a physiological fluid from said human host.
Claim 5
Dependent Claim
35 words
A method according to claim 1, wherein said DNA sequence is selected from the group consisting of the oncogenes src, fps, yes, fos, myc, erb, myb, rel, mos, bas, abl, ras, fes, fms, and sis.
Claim 6
Independent Claim
18 words
A method according to any of claims 1, 2, 3, or 4, wherein said probe is an antibody.
Claim 7
Dependent Claim
20 words
A method according to claim 5, wherein said antibody is labeled with a label capable of providing a detectible signal.
Claim 8
Independent Claim
27 words
A method according to any of claims 1, 2, 3, or 4, wherein said probe is a polynucleotide of at least 14 bases complementary to said mRNA.
Claim 9
Independent Claim
53 words
A method for evaluating the probability of leukemia in a human host, said method comprising: combining antibodies specific for the oncogene myb and blood cells from a human host suspected of having leukemia; and determining the level of binding of said antibodies to said host blood cells as diagnostic of a leukemic host.
Claim 10
Independent Claim
53 words
A method for evaluating the probability of leukemia in a human host, said method comprising: combining antibodies specific for the oncogene myb and blood cells from a human host suspected of having leukemia; and determining the level of binding of said antibodies to said host blood cells as diagnostic of a leukemic host.
Claim 11
Dependent Claim
26 words
A method according to claim 8, wherein said antibodies are produced in response to an oligopeptide mimicking a portion of the conformation of the myb protein.
Claim 12
Independent Claim
72 words
A method for substantially eliminating human malignant cells from a combination of human malignant and normal cells, which comprises: combining under cytotoxic conditions said combination of cells with an antibody specific for an expression product of a DNA sequence present in a retrovirus genome or substantially complementary to said DNA sequence, which sequence is expressed in said malignant cells as a surface protein; and isolating normal cells, substantially free of malignant cells.
Claim 13
Independent Claim
72 words
A method for substantially eliminating human malignant cells from a combination of human malignant and normal cells, which comprises: combining under cytotoxic conditions said combination of cells with an antibody specific for an expression product of a DNA sequence present in a retrovirus genome or substantially complementary to said DNA sequence, which sequence is expressed in said malignant cells as a surface protein; and isolating normal cells, substantially free of malignant cells.
Claim 14
Dependent Claim
19 words
A method according to claim 10, wherein said separation occurs in the presence of complement as said cytotoxic condition.
Claim 15
Dependent Claim
18 words
A method according to claim 10, wherein said antibodies are labeled with a radionuclide as said cytotoxic condition.
Claim 16
Independent Claim
19 words
A method according to any of claims 10, 11, or 12, wherein said DNA sequence is the myb gene.
Claim 17
Independent Claim
59 words
A method for treating a human host suspected of having malignant cells, which comprises: administering to said human host under cytotoxic conditions antibodies to the expression product of a gene, which gene is part of a retrovirus genome capable of inducing malignancy in a normal cell or which gene is substantially complementary to said gene of said retrovirus genome.
Claim 18
Independent Claim
59 words
A method for treating a human host suspected of having malignant cells, which comprises: administering to said human host under cytotoxic conditions antibodies to the expression product of a gene, which gene is part of a retrovirus genome capable of inducing malignancy in a normal cell or which gene is substantially complementary to said gene of said retrovirus genome.
Claim 19
Dependent Claim
15 words
A method according to claim 14, wherein said cytotoxic condition is the presence of complement.
Claim 20
Dependent Claim
22 words
Antibodies specific for the expression product of the human oncogenes c-myc, c-fos, c-ras Ha , c-ras Ki , c-fes, c-myb, and c-src.
Claim 21
Dependent Claim
22 words
Antibodies specific for the expression product of the human oncogenes c-myc, c-fos, c-ras Ha , c-ras Ki , c-fes, c-myb, and c-src.
Claim 22
Dependent Claim
15 words
Antibodies according to claim 16, labeled with a label capable of providing a detectible signal.
Claim 23
Dependent Claim
10 words
Antibodies according to claim 16, labeled with a cytotoxic agent.
Claim 24
Dependent Claim
47 words
An antigenic oligopeptide selected from the class consisting of: (a) met-ala-phe-ala-his-asn-pro-pro-ala-gly-pro-leu-pro-gly-ala (b) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lsy-met-his-gly-gly-ala-va (c) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lys-met (d) asp-asn-thr-arg-thr-ser-gly-asp-asn-ala-pro-val-ser-cys-leu-gly-glu (e) arg-leu-ileu-glu-asp-asn-glu-tyr-thr-ala-arg-gln-gly-ala-lys-phe-pro (f) trp-arg-arg-asp-pro-glu-glu-arg-pro-thr (g) arg-leu-lys-lys-ileu-ser-lys-glu-glu-lys-thr-pro-gly-cys-val-lys-ileu-lys-lys (h) asp-leu-pro-ser-arg-thr-val-asp-thr-lys-gln-ala-gln-glu-leu-ala-arg (i) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-ser-gly-val-gly-lys-ser-ala (j) glu-asp-ileu-his-gln-try-arg-glu-gln-ileu-lys-arg-val-lys-asp-ser-asp-asp (k) val-arg-glu-ileu-arg-gln-his-lys-leu-arg-lys-leu-asn-pro-pro-asp-glu-ser-gly-pro (l) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-gly-gly-val-gly-lys-ser-ala (m) val-asp-glu-tyr-asp-pro-thr-ileu-glu-asp-ser-tyr-arg-lys-gln-val (n) arg-his-ser-thr-ser-ser-ser-glu-gln-glu-arg-glu-gly-gly-arg (o) asn-gln-gln-thr-arg-glu-phe-val-glu-lys-gly-gly-arg (p) pro-glu-val-gln-lys-pro-leu-his-glu-gln (q) ala-ser-pro-tyr-pro-asn-leu-ser-asn-gln-gln-thr-arg (r) arg-leu-ileu-ala-glu-lys-glu-gln-leu-arg-arg-arg-arg-glu-gln (s) asn-asn-glu-lys-ala-pro-lys-val-val.
Claim 25
Dependent Claim
47 words
An antigenic oligopeptide selected from the class consisting of: (a) met-ala-phe-ala-his-asn-pro-pro-ala-gly-pro-leu-pro-gly-ala (b) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lsy-met-his-gly-gly-ala-va (c) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lys-met (d) asp-asn-thr-arg-thr-ser-gly-asp-asn-ala-pro-val-ser-cys-leu-gly-glu (e) arg-leu-ileu-glu-asp-asn-glu-tyr-thr-ala-arg-gln-gly-ala-lys-phe-pro (f) trp-arg-arg-asp-pro-glu-glu-arg-pro-thr (g) arg-leu-lys-lys-ileu-ser-lys-glu-glu-lys-thr-pro-gly-cys-val-lys-ileu-lys-lys (h) asp-leu-pro-ser-arg-thr-val-asp-thr-lys-gln-ala-gln-glu-leu-ala-arg (i) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-ser-gly-val-gly-lys-ser-ala (j) glu-asp-ileu-his-gln-try-arg-glu-gln-ileu-lys-arg-val-lys-asp-ser-asp-asp (k) val-arg-glu-ileu-arg-gln-his-lys-leu-arg-lys-leu-asn-pro-pro-asp-glu-ser-gly-pro (l) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-gly-gly-val-gly-lys-ser-ala (m) val-asp-glu-tyr-asp-pro-thr-ileu-glu-asp-ser-tyr-arg-lys-gln-val (n) arg-his-ser-thr-ser-ser-ser-glu-gln-glu-arg-glu-gly-gly-arg (o) asn-gln-gln-thr-arg-glu-phe-val-glu-lys-gly-gly-arg (p) pro-glu-val-gln-lys-pro-leu-his-glu-gln (q) ala-ser-pro-tyr-pro-asn-leu-ser-asn-gln-gln-thr-arg (r) arg-leu-ileu-ala-glu-lys-glu-gln-leu-arg-arg-arg-arg-glu-gln (s) asn-asn-glu-lys-ala-pro-lys-val-val.
Claim 26
Dependent Claim
51 words
Antibodies raised to an antigenic polypeptide selected from the class consisting of: (a) met-ala-phe-ala-his-asn-pro-pro-ala-gly-pro-leu-pro-gly-ala; (b) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lys-met-his-gly-gly-ala-val; (c) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lys-met; (d) asp-asn-thr-arg-thr-ser-gly-asp-asn-ala-pro-val-ser-cys-leu-gly-glu; (e) arg-leu-ileu-glu-asp-asn-glu-tyr-thr-ala-arg-gln-gly-ala-lys-phe-pro; (f) trp-arg-arg-asp-pro-glu-glu-arg-pro-thr; (g) arg-leu-lys-lys-ileu-ser-lys-glu-glu-lys-thr-pro-gly-cys-val-lys-ileu-lys-lys; (h) asp-leu-pro-ser-arg-thr-val-asp-thr-lys-gln-ala-gln-glu-leu-ala-arg; (i) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-ser-gly-val-gly-lys-ser-ala; (j) glu-asp-ileu-his-gln-tyr-arg-glu-gln-ileu-lys-arg-val-lys-asp-ser-asp-asp; (k) val-arg-glu-ileu-arg-gln-his-lys-leu-arg-lys-leu-asn-pro-pro-asp-glu-ser-gly-pro; (l) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-gly-gly-val-gly-lys-ser-ala; (m) val-asp-glu-tyr-asp-pro-thr-ileu-glu-asp-ser-tyr-arg-lys-gln-val; (n) arg-his-ser-thr-ser-ser-ser-glu-gln-glu-arg-glu-gly-gly-arg; (o) asn-gln-gln-thr-arg-glu-phe-val-glu-lys-gly-gly-arg; (p) pro-glu-val-gln-lys-pro-leu-his-glu-gln; (q) ala-ser-pro-tyr-pro-asn-leu-ser-asn-gln-gln-thr-arg; (r) arg-leu-ileu-ala-glu-lys-glu-gln-leu-arg-arg-arg-arg-glu-gln; and (s) asn-asn-glu-lys-ala-pro-lys-val-val.
Claim 27
Dependent Claim
51 words
Antibodies raised to an antigenic polypeptide selected from the class consisting of: (a) met-ala-phe-ala-his-asn-pro-pro-ala-gly-pro-leu-pro-gly-ala; (b) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lys-met-his-gly-gly-ala-val; (c) pro-phe-his-lys-asp-gln-thr-phe-thr-glu-tyr-arg-lys-met; (d) asp-asn-thr-arg-thr-ser-gly-asp-asn-ala-pro-val-ser-cys-leu-gly-glu; (e) arg-leu-ileu-glu-asp-asn-glu-tyr-thr-ala-arg-gln-gly-ala-lys-phe-pro; (f) trp-arg-arg-asp-pro-glu-glu-arg-pro-thr; (g) arg-leu-lys-lys-ileu-ser-lys-glu-glu-lys-thr-pro-gly-cys-val-lys-ileu-lys-lys; (h) asp-leu-pro-ser-arg-thr-val-asp-thr-lys-gln-ala-gln-glu-leu-ala-arg; (i) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-ser-gly-val-gly-lys-ser-ala; (j) glu-asp-ileu-his-gln-tyr-arg-glu-gln-ileu-lys-arg-val-lys-asp-ser-asp-asp; (k) val-arg-glu-ileu-arg-gln-his-lys-leu-arg-lys-leu-asn-pro-pro-asp-glu-ser-gly-pro; (l) met-thr-glu-tyr-lys-leu-val-val-val-gly-ala-gly-gly-val-gly-lys-ser-ala; (m) val-asp-glu-tyr-asp-pro-thr-ileu-glu-asp-ser-tyr-arg-lys-gln-val; (n) arg-his-ser-thr-ser-ser-ser-glu-gln-glu-arg-glu-gly-gly-arg; (o) asn-gln-gln-thr-arg-glu-phe-val-glu-lys-gly-gly-arg; (p) pro-glu-val-gln-lys-pro-leu-his-glu-gln; (q) ala-ser-pro-tyr-pro-asn-leu-ser-asn-gln-gln-thr-arg; (r) arg-leu-ileu-ala-glu-lys-glu-gln-leu-arg-arg-arg-arg-glu-gln; and (s) asn-asn-glu-lys-ala-pro-lys-val-val.
Claim 28
Dependent Claim
15 words
Antibodies according to claim 20, labeled with a label capable of providing a detectible signal.
Claim 29
Dependent Claim
10 words
Antibodies according to claim 20, labeled with a cytotoxic agent.
References Cited (Backward Citations)
GB2034323A
Cited
US4331647A
Cited
US4348376A
Cited
US4361544A
Cited
US4358535A
Cited
US4358535B1
Cited
US4535058A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-10-12 | 1991-04-13 | 1991-10-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-10-12 | 1995-04-13 | 1995-10-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-10-12 | 1999-04-13 | 1999-10-13 | $7700.00 | Window Closed / Lapsed |